We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

18 hedge funds and large institutions have $2.58M invested in Processa Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 18 → 18 (0)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

20% less capital invested

Capital invested by funds: $3.24M → $2.58M (-$657K)

Holders
18
Holders Change
–
Holders Change %
0%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$36.8K
2
TRCT
Tower Research Capital (TRC)
New York
+$8.82K

Top Sellers

Rank Fund Capital Flow
1
VRM
Vectors Research Management
New York
-$11K
2
BlackRock
BlackRock
New York
-$1.47K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$845K – – –
ACM
2
AIGH Capital Management
Maryland
$686K – – –
WVP
3
Worth Venture Partners
New Jersey
$160K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$146K – – –
VCA
5
Verdence Capital Advisors
Maryland
$135K – – –
CBA
6
Coastal Bridge Advisors
Connecticut
$119K – – –
Morgan Stanley
7
Morgan Stanley
New York
$111K – – –
Janney Montgomery Scott
8
Janney Montgomery Scott
Pennsylvania
$104K – – –
State Street
9
State Street
Massachusetts
$97K – – –
BlackRock
10
BlackRock
New York
$63K -$1.47K -1 -2%
Northern Trust
11
Northern Trust
Illinois
$35K – – –
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$28K +$36.8K +25 New
Renaissance Technologies
13
Renaissance Technologies
New York
$26K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$10K +$8.82K +6 +200%
Wells Fargo
15
Wells Fargo
California
$7K – – –
EIM
16
Essex Investment Management
Massachusetts
$5K – – –
AF
17
Allworth Financial
California
$4K – – –
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$2K – – –
VRM
19
Vectors Research Management
New York
– -$11K -8 Closed

PCSA Hedge Fund Activity: Q3 2022 in Review

18 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q3 2022, worth a combined $2.58M — down 20% from $3.24M a quarter earlier.

Fund positioning in PCSA was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Dimensional Fund Advisors, opening a new position worth an estimated $36.8K. The largest seller was Vectors Research Management, exiting entirely with an estimated $11K sold.

  • 18 institutional investors held Processa Pharmaceuticals (PCSA) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $2.58M of Processa Pharmaceuticals stock for Q3 2022, down 20% quarter-over-quarter.
  • 1 fund opened new Processa Pharmaceuticals positions in Q3 2022 and 1 closed out, a net change of 0 holders.
  • The largest Processa Pharmaceuticals buyer in Q3 2022 was Dimensional Fund Advisors, an estimated $36.8K added.
  • The largest Processa Pharmaceuticals seller in Q3 2022 was Vectors Research Management, an estimated $11K sold.

Based on aggregated 13F filings for Q3 2022.